September 20, 2018 / 8:01 AM / a month ago

Mylan, Fujifilm win EU okay for copy of AbbVie's Humira

LONDON, Sept 20 (Reuters) - Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won European approval to market a cheaper copy of AbbVie's $18-billion-a-year biologic drug Humira, the world's best-selling prescription medicine.

Their version of the product, which is set for launch in Europe on or after Oct. 16, is the fifth so-called biosimilar copy of Humira. The large number of copies reflects intense competition among rivals for a slice of a huge market.

Amgen, Novartis's generics wing Sandoz, South Korea's Samsung Bioepis and Germany's Boehringer Ingelheim have already won approval for four other biosimilars to Humira.

Humira is used to treat a range of conditions including rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis. (Reporting by Ben Hirschler; editing by Jason Neely)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below